Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:CMHC -2.89%81 Shiller PE Ratio is 173.03 as of Aug. 18, 2026, which is 512% above its 10-year median of 28.27. GuruFocus rates XSWX:CMHC with a GF Score™ of 81/100 and a GF Value™ of CHF40.77 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 532 Drug Manufacturers companies, Cosmo NV ranks worse than 96.99% on this metric.
As of today (2026-08-18), Cosmo NV's current share price is CHF57.10. Cosmo NV's E10 for the fiscal year that ended in Dec25 was CHF0.33. Cosmo NV's Shiller PE Ratio for today is 173.03.
The historical rank and industry rank for Cosmo NV's Shiller PE Ratio or its related term are showing as below:
XSWX:CMHC'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.61 Med: 28.27 Max: 361.21
Current: 177.54
During the past 13 years, Cosmo NV's highest Shiller PE Ratio was 361.21. The lowest was 10.61. And the median was 28.27.
XSWX:CMHC's Shiller PE Ratio is ranked worse than 96.99% of 532
companies
in the Drug Manufacturers industry
Industry Median: 25.695
vs XSWX:CMHC: 177.54
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Cosmo NV's adjusted earnings per share data of for the fiscal year that ended in Dec25 was CHF-0.211. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF0.33 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Cosmo NV Shiller PE Ratio Related Terms
Cosmo NV Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CMHC vs LLY, JNJ, ABBV: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Cosmo NV's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV's E10 for the fiscal year that ended in Dec25 is calculated as:
For example, Cosmo NV's adjusted earnings per share data for the fiscal year that ended in Dec25 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Cosmo NV (XSWX:CMHC) has a Shiller PE Ratio of 173.03 as of Aug. 18, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Cosmo NV and its competitors. This is 512% above median its historical median of 28.27. Over the past decade, Cosmo NV's Shiller PE Ratio has ranged from 10.61 to 361.21. According to the industry distribution chart, Cosmo NV ranks #516 out of 532 companies in the Drug Manufacturers industry, placing it in the top 97%.
Is Cosmo NV's Shiller PE Ratio too high?
Cosmo NV's current Shiller PE Ratio of 173.03 is 512% above median its 10-year median of 28.27. Over the past 10 years, this metric has ranged from a low of 10.61 to a high of 361.21. The Drug Manufacturers industry median Shiller PE Ratio is 25.70. Cosmo NV's value of 173.03 is 573.4% above this industry median. Based on the distribution chart, Cosmo NV ranks #516 out of 532 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Shiller PE Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #516 out of 532 companies for Shiller PE Ratio. This places Cosmo NV in the lower half of its industry. The industry median Shiller PE Ratio is 25.70. Cosmo NV's value of 173.03 is 573.4% above this benchmark. Historically, Cosmo NV's own Shiller PE Ratio has ranged from 10.61 to 361.21 over the past decade. While the company's 10-year median is 28.27 vs. the industry median of 25.70, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.70, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Shiller PE Ratio of 173.03 is 573.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Shiller PE Ratio is 173.03, which is 512% above median its own 10-year median of 28.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:CMHC) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.77, compared to a current price of CHF57.10 — trading 40.1% above its estimated fair value. The current Shiller PE Ratio is 173.03, which is 512% above median its 10-year median of 28.27 and 573.4% above the Drug Manufacturers industry median of 25.70. Cosmo NV's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Cosmo NV (XSWX:CMHC), the current Shiller PE Ratio is 173.03 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:CMHC) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF57.10 is trading 40.1% above its estimated GF Value™ of CHF40.77.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:CMHC:
Shiller PE Ratio: 173.03 (512% above median its 10-year median of 28.27)
GF Value™: CHF40.77 vs. price of CHF57.10 (40.1% above fair value)
Industry Position: 573.4% above the Drug Manufacturers median (#516 of 532)
No single metric tells the full story. See the XSWX:CMHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
81GF Score
Get the complete analysis for XSWX:CMHC
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CMHC has been successfully added to your 
